BridgeBio Pharma
BBIO
BBIO
88 hedge funds and large institutions have $3.67B invested in BridgeBio Pharma in 2019 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 31 increasing their positions, 16 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
88
Holders Change
+13
Holders Change %
+17.33%
% of All Funds
1.74%
Holding in Top 10
7
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+40%
% of All Funds
0.14%
New
29
Increased
31
Reduced
16
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$94.2M |
| 2 |
BlackRock
New York
|
+$41.5M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.2M |
| 4 |
State Street
Boston,
Massachusetts
|
+$16M |
| 5 |
Nuveen Asset Management
Chicago,
Illinois
|
+$15.7M |
Top Sellers
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$24.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.6M |
| 3 |
SM
SCGE Management
Menlo Park,
California
|
-$8.93M |
| 4 |
DM
Deerfield Management
New York
|
-$6.23M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.67M |
